Daniel J. Fullen

The manufacturing of human viral challenge agents for use in clinical studies to accelerate the drug development process

Andrew P. Catchpole, Daniel J. Fullen, Nicolas Noulin, 2018, BMC Research Notes.

Risk Factors Associated with Severe Clinical Outcomes of Pandemic H1N1 Infection

Daniel J. Fullen, Rob Lambkin-Williams, 2014 .

A role for endoplasmic reticulum exit sites in foot-and-mouth disease virus infection

Daniel J. Fullen, D. Stephens, Katy Moffat, 2013, The Journal of general virology.

Melatonin for Neonatal Encephalopathy: From Bench to Bedside

Daniel J. Fullen, X. Golay, N. Robertson, 2021, International journal of molecular sciences.

A Tool for Investigating Asthma and COPD Exacerbations: A Newly Manufactured and Well Characterised GMP Wild-Type Human Rhinovirus for Use in the Human Viral Challenge Model

Daniel J. Fullen, Rob Lambkin-Williams, A. Mann, 2016, PloS one.

Correction: Accelerating Influenza Research: Vaccines, Antivirals, Immunomodulators and Monoclonal Antibodies. The Manufacture of a New Wild-Type H3N2 Virus for the Human Viral Challenge Model

Daniel J. Fullen, Rob Lambkin-Williams, A. Mann, 2016, PloS one.

Accelerating Influenza Research: Vaccines, Antivirals, Immunomodulators and Monoclonal Antibodies. The Manufacture of a New Wild-Type H3N2 Virus for the Human Viral Challenge Model

Daniel J. Fullen, Rob Lambkin-Williams, A. Mann, 2016, PloS one.

The manufacturing of human viral challenge agents for use in clinical studies to accelerate the drug development process

Daniel J. Fullen, Rob Lambkin-Williams, A. Mann, 2018, BMC Research Notes.